Skyhawk Therapeutics
Updated: December 02, 2025
The team
Country: USA | Funding: $181.2M (+)
Founded: 2016
Website: https://www.skyhawktx.com/
Skyhawk develops small molecule therapeutics that modulate RNA expression for treatment of cancer, neurological diseases and rare diseases. The company's flagship RNA-targeting drug for Huntington's disease is currently in Phase III clinical trials. Skyhawk's platform consists of: SKYSTAR - system for identifying priority RNA targets, SKYLIBRARY - library of compounds for RNA targets, SKYSEQ - multiplex screening system that simultaneously tests dozens of important targets across various RNA motifs to identify compounds selective for a specific disease target and SKYAI - machine learning model that integrates data from SKYSTAR, medicinal chemistry, animal studies, toxicology studies and clinical programs to develop the next generation of novel RNA splicing modulators.
Founded: 2016
Website: https://www.skyhawktx.com/
Skyhawk develops small molecule therapeutics that modulate RNA expression for treatment of cancer, neurological diseases and rare diseases. The company's flagship RNA-targeting drug for Huntington's disease is currently in Phase III clinical trials. Skyhawk's platform consists of: SKYSTAR - system for identifying priority RNA targets, SKYLIBRARY - library of compounds for RNA targets, SKYSEQ - multiplex screening system that simultaneously tests dozens of important targets across various RNA motifs to identify compounds selective for a specific disease target and SKYAI - machine learning model that integrates data from SKYSTAR, medicinal chemistry, animal studies, toxicology studies and clinical programs to develop the next generation of novel RNA splicing modulators.
